Genome-wide association studies have revealed disease-associated mutations in PSEN1, APP, APOE (Apolipoprotein E), and TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) [71], well-studied proteins that are the focus of therapeutic intervention for AD [72,73,74,75]. This evidence concerns the gene PSEN1 and Alzheimer disease.